Resources

All Resources

Our resource hub to discover reports, policy papers and other forms of informative content

Filter by

PMPRB Notice and Comment Response

Innovative Medicines Canada opposes a July 15, 2021 proposal to change international price tests for existing medicines and their line extensions from the highest of the international schedule to the median.

Learn more|View

2022 Federal Pre-Budget Consultation

Our industry calls on the federal government to implement measures under the Biomanufacturing and Life Sciences Strategy to build a more vibrant life sciences sector and enhance patients’ access to innovative medicines.

Learn more|View

ISED Consultation on Biomanufacturing

IMC encourages the federal government to commit to building Canada’s domestic life sciences sector and manufacturing capacity. This follows IMC’s proposal in fall 2020 to establish a public-private biomanufacturing accelerator.

Learn more|View

2021 Federal Pre-Budget Consultation

The industry calls on the federal government to delay implementation of PMPRB regulatory changes until the COVID-19 pandemic has abated. IMC urges the federal government to work with our industry to build a more vibrant life sciences sector – one that enhances patients’ access to innovative medicines and tackles the sector’s critical issues.

Learn more|View

House of Commons Standing Committee on Health (HESA)

The industry campaigns to remove experimental “new economic factors” from regulations – the source of most stakeholder concerns amid 2020 PMPRB changes. IMC encourages government to delay implementation of changes until the COVID-19 pandemic has abated.

Learn more|View

resources

Discover. Learn.
Understand.

Informative content to keep you up to date on the most pressing issues facing our industry.